IP Library Granted Patent US 7,594,934
Granted Patent B2
US 7,594,934 · App. 10/517,863 · Granted Sep 29, 2009

Galactosidase-treated prosthetic devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,594,934
App. No.
10/517,863
Granted
Sep 29, 2009
Kind
B2
Abstract

Matrix material for a substantially immunologically-compatible meniscal augmentation device of biocompatible and partially bioresorbable fibers is prepared by treatment with oc-galactosidase to eliminate oc-Gal epitopes. Upon implantation into a segmental defect of a meniscus, the composite of the meniscal augmentation device and the meniscus establishes a scaffold adapted for ingrowth of meniscal fibrochondrocytes.

Claims (11)

1. A substantially non-immunogenic prosthetic device for implantation into a vertebrate subject in a region disposed between and connecting two of the subject's bones, comprising a biocompatible glycosidase-treated matrix material, wherein the device matrix is adapted to have an in vivo an outer surface contour substantially the same as that of region disposed between and connecting two of the subject's bones, wherein the device is a prosthetic ligament comprising a plurality of substantially aligned, elongated filaments,

(a) wherein the fibrils are present in the matrix at a concentration of about 75 to 100% by dry weight, and

(b) wherein polysaccharide molecules in the matrix are present at a concentration of about 0 to 25% by dry weight.

2. A substantially non-immunogenic prosthetic device for implantation into a vertebrate subject in a region disposed between and connecting two of the subject's bones, comprising a biocompatible glycosidase-treated matrix material, wherein the device matrix is adapted to have an in vivo an outer surface contour substantially the same as that of a region disposed between and connecting two of the subject's bones wherein the device is a prosthetic articular cartilage device adapted to have an in vivo outer surface contour substantially the same as that of natural articular cartilage further comprising a biocompatible conical base component including an anchor for anchoring the articular cartilage device in a complimentary aperture in cancellous bone, the base component extending from portions of the outer surface of the matrix.

3. The device of claim 2 , wherein the base component is at least partially resorbable.

4. The device of claim 2 , wherein the base component includes a plurality of circumferentially extending ridges.

5. The device of claim 2 , wherein the base component is composed of a composite material, comprising:

(a) a dispersion of collagen and a

(b) composition which is selected from the group consisting of tricalcium phosphate hydroxyapatite, and a combination of tricalcium phosphate and hydroxyapatite.

6. The device of claim 5 , wherein the dispersion comprises about 90% by weight tricalcium phosphate and about 10% by weight collagen.

7. The device of claim 5 , wherein the dispersion comprises about 90% by weight hydroxyapatite and about 10% by weight collagen.

Assignments (3)
CHANGE OF NAME Recorded Jun 25, 2010
From: CROSSCART, INC.
To: APERION BIOLOGICS, INC.
Reel/Frame 024588/0851 →
CHANGE OF NAME Recorded Jan 12, 2010
From: CROSSCART, INC.
To: APERION BIOLOGICS, INC.
Reel/Frame 023758/0636 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2005
From: STONE, KEVIN R.
To: CROSSCART, INC.
Reel/Frame 016654/0456 →